Cardiovascular · Investigational
Atrial Natriuretic Peptide (ANP)
No lawful US pathway
01 · Overview
Atrial natriuretic peptide is a 28-amino acid hormone secreted mainly by atrial cardiomyocytes, one of the two classic cardiac natriuretic peptides along with BNP (PMID 32444692). It binds membrane guanylyl cyclase receptors that signal through intracellular cyclic GMP, mediating vasodilation, sodium excretion, and suppression of renin and aldosterone (PMID 32444692).
ANP is central to the endocrine function of the heart in volume and blood pressure regulation.
02 · Research summary & key findings
Plasma natriuretic peptide levels are established diagnostic and prognostic biomarkers in heart disease (PMID 32444692). As a therapy, recombinant ANP (carperitide) is marketed in Japan but not approved by the FDA, and evidence of clinical benefit in acute heart failure is weak, with a meta-analysis showing no improvement in mortality or rehospitalization (PMID 41310450). A Japanese multicenter randomized trial of low-dose ANP infusion for kidney injury after cardiac surgery increased urine output but did not improve renal function or other outcomes (PMID 27997877).
03 · Regulatory status
Atrial Natriuretic Peptide (ANP) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Atrial Natriuretic Peptide (ANP) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding.
See the 4 FDA-approved compounds in Cardiovascular
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
04 · Administration routes
- Endogenous
References
- [1]Effects of low-dose atrial natriuretic peptide infusion on cardiac surgery-associated acute kidney injury: A multicenter randomized controlled trial J Crit Care, 2017. PMID 27997877
- [2]Cardiac natriuretic peptides Nat Rev Cardiol, 2020. PMID 32444692
- [3]Effect of carperitide on clinical outcomes among patients with acute heart failure: a meta-analysis of randomized and propensity‑matched studies BMC Cardiovasc Disord, 2025. PMID 41310450
Primary literature
- PubMed: "Atrial Natriuretic Peptide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Atrial Natriuretic Peptide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Atrial Natriuretic Peptide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Cardiovascular
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.